Prostate Cancer Clinical Trial

Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

Summary

In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males age 45-80 years
Diagnosis of prostate cancer
Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation
Baseline AUA score< or =12
May be on antiandrogenand/or alpha reductase therapy
Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent -

Exclusion Criteria:

History of insulin-dependent diabetes
Uncontrolled hypertention
History of symptomtic hypotension (including syncope and dizziness)
Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention
Pre-existing prostatitis either continuous or intermittent
Concurrent use of any other anticholinergics
previous or concurrent usage of LHRH agonist

Study is for people with:

Prostate Cancer

Estimated Enrollment:

60

Study ID:

NCT00264017

Recruitment Status:

Completed

Sponsor:

Dattoli Cancer Center and Brachytherapy Research Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Dattoli Cancer Center and Brachytherapy Research Institute
Sarasota Florida, 34237, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

60

Study ID:

NCT00264017

Recruitment Status:

Completed

Sponsor:


Dattoli Cancer Center and Brachytherapy Research Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider